reMYND is a biotechnology company focused on developing treatments for Huntington's disease, epilepsy, and other conditions caused by cellular dysfunction. The company leverages a proprietary drug discovery platform to identify novel targets and create first-in-class small molecules. Its most advanced program, ReS19 T, is an investigational compound currently in CTA enabling studies for the treatment of Alzheimer's disease. Additionally, reMYND operates a dedicated Contract Research Organization (CRO) that specializes in central nervous system (CNS) disorders. The CRO assists clients in evaluating the pharmacokinetics, pharmacodynamics, and efficacy of their experimental treatments using proprietary animal models. reMYND's CRO serves a global client base, including top pharmaceutical companies in the US, Europe, and Japan. The company has received substantial support from grants provided by VLAIO, the European Union, and The Michael J. Fox Foundation.

reMYND's business model involves both drug development and contract research services. The company generates revenue through the development and licensing of its proprietary treatments, as well as through its CRO services, which provide critical data and insights for pharmaceutical companies developing CNS treatments.

Keywords: biotechnology, drug discovery, Huntington's disease, epilepsy, CNS disorders, Alzheimer's, CRO services, pharmacokinetics, pharmacodynamics, animal models, global clients.